Navigation Links
Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
Date:9/6/2008

Results Demonstrate Safety and Efficacy of First-in-Class Neurally Acting

Anti-Migraine Agent (NAAMA) for the Treatment of Acute Migraine

LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing vasoconstriction. COL-144 is a highly potent and selective 5HT1F receptor agonist. The studies were presented in poster presentations at the European Headache and Migraine Trust International Congress 2008 in London, Sept. 4-7, 2008.

"In the Phase II study, the majority of patients experienced migraine relief 20 to 40 minutes after dosing and COL-144 was generally well-tolerated," Alison Pilgrim, BM, BCh, DPhil, chief medical officer at CoLucid, said. "The study indicates that COL-144 may be a treatment option for all patients including those who don't respond to or are contraindicated for the current standard of care."

The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and received 2.5 to 45 mg of COL-144 or placebo as an intravenous infusion over 20 minutes as first-line treatment of an acute migraine attack. The primary end-point parameter was headache response, defined as a reduction in headache severity from moderate to severe at baseline to mild or no headache at two hours after initiation of infusion of study drug.

A higher proportion of patients showed a headache response at two hours post dose in the 10 mg, 20 mg, 30 mg and 45 mg groups compared to placebo (54.2 to 75% vs. 45.2%) with a statistically significant linear association between response rates and
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 For the pharmaceutical industry, marketplace ... with payers. Likewise, the importance of the managed markets function ... continue to grow as payer formularies and provider networks play ... At the same time, managed markets leaders must continually ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... (NASDAQ: DCTH ) today announced the Therapeutic ... approved the Delcath Hepatic CHEMOSAT® Delivery system for listing ... TGA,s approval allows Delcath to market and sell the ... Australia represents another achievement for Delcath as we seek ...
... Feb. 14, 2012  Intellect Neurosciences, Inc. (OTCBB: ILNS), ... development of disease-modifying therapeutic agents for the treatment ... that it submitted a statement setting out its ... preliminary decision to revoke the company,s ANTISENILIN® patents ...
Cached Medicine Technology:Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia 2Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia 3Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings 2Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings 3Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings 4
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
(Date:1/22/2015)... Richmond, VA (PRWEB) January 22, 2015 ... the power at the Science Museum of Virginia. Wicked ... 24. , Wicked Plants unearths 75 poisonous, carnivorous and ... traverse through each room to uncover the biochemical, physical ...
(Date:12/26/2014)... 26, 2014 It is said that nothing ... Today, UWDress.com, the famous wedding dress supplier, shows its ... site-wide cocktail gown promotion. , UWDress.com’s navy cocktail gowns ... they come in high fashion styles. Simple dresses in bright ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2
... improvements and less cell degeneration , , SUNDAY, Feb. ... appears able to slow or stop Alzheimer,s disease in ... The brain,s entorhinal cortex, which supports memory, normally produces ... decrease when Alzheimer,s is present. When researchers injected BDNF ...
... Trust for America,s Health released the following statement after ... cut more than $100 billion from the American Recovery ... the Senate struck a final bargain to strip all ... plan, failing to recognize that this funding would have ...
... pain and swelling , , FRIDAY, Feb. 6 (HealthDay News) ... symptoms in people with rheumatoid arthritis (RA) has been ... study included two postmenopausal women with advanced RA. Researchers ... women,s affected joints. IL-1Ra protein blocks the actions of ...
... Aflac Incorporated,announced today that it is providing expanded detail ... The company has elevated additional ... and Tier 1 perpetual debenture, including CUSIP numbers for ... The company has also,prepared and elevated a frequently asked ...
... Supplies tend to run dangerously short this time of year , , ... gone, and everyone has settled back into regular routines. , But ... this time of the year. , The nation,s blood supply tends ... to a decline in donations. Now that the new year is ...
... with low glycemic index sweeteners and berries to produce a new type ... benefits of berry antioxidants and probiotics are also discussed with comments from ... ... long been regarded as a sweet and sinful indulgence. Everyone knows ...
Cached Medicine News:Health News:Brain Protein May Have Potential Against Alzheimer's 2Health News:Gene Therapy May Ease Rheumatoid Arthritis 2Health News:Aflac Incorporated Provides Added Detail on Perpetual Debenture Holdings 2Health News:Needed: Blood Donations 2Health News:Needed: Blood Donations 3Health News:Losing Weight with Chocolate on Valentine's Day 2
... Choice for Urinary Tract Infection ... Line. A multi-center study was ... potential UTIs. There were 1,887 ... leukocyte and nitrite results of ...
... busy physician's office environment, interruptions ... to timing errors and variability ... are read visually. Studies have ... performed with an instrument, sensitivity ...
Keep your laboratory efficient. And meet your volume needs. When you set the pace with the Clinitek 500 Urine Chemistry Analyzer. Its ready when you are. No warm-up. No calibration. No bells. Just pr...
... These dual pressure sensor ... sampling/slow-speed injection, slow-speed injection/guide wire, ... model SPC-784A for high-speed injection ... side openings and an open-end ...
Medicine Products: